Epigenetic Reprogramming and ER-100: Can Yamanaka Factors Reverse Ageing?

TL;DR: In 2026, Life Biosciences dosed the first human patient with ER-100, a gene therapy that uses partial epigenetic reprogramming to try to restore youthful function in damaged optic nerves. The trial targets glaucoma and non-arteritic anterior ischaemic optic neuropathy (NAION). This is the first time Yamanaka-factor reprogramming has been tested in people. If it works safely, it could open the door to treating many age-related diseases — but it is years away from any longevity or "anti-aging" application.

1. What Is Epigenetic Reprogramming?

Every cell in your body carries the same DNA, but different cell types read different parts of that DNA. Epigenetics — the pattern of chemical tags such as DNA methylation and histone modifications — controls which genes are turned on or off.

As we age, these tags drift and become disorganised. This "epigenetic noise" is thought to contribute to:

• Loss of cellular identity and function
• Reduced tissue repair
• Chronic inflammation
• Increased cancer risk

Epigenetic reprogramming aims to reset these tags back to a more youthful pattern. The challenge is doing it without turning cells into stem cells or triggering cancer.

2. Yamanaka Factors: The Discovery That Made Reprogramming Possible

In 2006, Shinya Yamanaka showed that just four proteins — OCT4, SOX2, KLF4 and c-MYC — could reprogram adult cells into induced pluripotent stem cells (iPSCs). He won the Nobel Prize for this work.

The four factors are powerful enough to wipe the epigenetic slate clean. But used at full strength, they can:

• Erase cell identity (a skin cell forgets it is a skin cell)
• Promote tumours, especially through c-MYC
• Disrupt normal tissue function

The breakthrough for ageing was the idea of partial reprogramming: express Yamanaka factors briefly and intermittently, enough to rejuvenate cells but not enough to make them pluripotent. David Sinclair's lab at Harvard and others have shown this can reverse age-related markers in mouse eye, muscle, kidney and other tissues.

3. ER-100: The First Human Trial

ER-100 (also called AAV2-OSK) is an adeno-associated virus gene therapy developed by Life Biosciences. It delivers three Yamanaka factors — OCT4, SOX2 and KLF4 — but leaves out the cancer-associated factor c-MYC.

Key facts about the trial:

• Target condition: open-angle glaucoma and non-arteritic anterior ischaemic optic neuropathy (NAION).
• Delivery: intravitreal injection into the eye, a relatively contained and monitorable site.
• IND cleared: the FDA cleared the IND in late 2025/early 2026 (Life Biosciences press release).
• First patient dosed: Life Biosciences announced the first patient was dosed in 2026 (Life Biosciences announcement).
• Trial ID: NCT07290244 on ClinicalTrials.gov.

The eye is a logical first target because it is accessible, the cells are well studied, and vision loss is a clear, measurable endpoint. Success here would not mean a whole-body rejuvenation therapy is imminent, but it would prove the principle in humans.

4. Animal Evidence for Partial Reprogramming

Before ER-100, partial reprogramming showed dramatic results in animals:

• Vision restoration: in mice with glaucoma-like optic nerve injury, Sinclair's lab reported that OSK reprogramming restored visual function and reversed age-related changes in retinal ganglion cells.
• Muscle and kidney: other studies found improved regeneration and reduced age markers in muscle and kidney after partial reprogramming.
• No teratomas: partial, cyclic reprogramming did not produce tumours or erase cell identity in these short-term studies, unlike continuous full reprogramming.

These studies established the biological plausibility that moved regulators to allow the first human trial.

5. Risks and Open Questions

This is uncharted territory. Key concerns include:

• Cancer: even without c-MYC, forced expression of pluripotency factors could theoretically promote tumour formation or de-differentiation.
• Immune response: the AAV vector and the foreign OSK proteins may trigger inflammation or neutralising antibodies.
• Loss of cell identity: if reprogramming goes too far, retinal cells could lose their specialised function.
• Durability: even if the therapy works, the effects may fade as epigenetic noise reaccumulates.
• Delivery to other organs: the eye is a small, enclosed target. Treating the brain, heart, liver or whole body is far more complex.

6. What This Means for Longevity

Epigenetic reprogramming is the most ambitious anti-aging strategy in development. If partial reprogramming proves safe and effective, it could theoretically treat multiple age-related diseases at once by addressing their common root cause: cellular ageing.

But the timeline is long:

• Eye trials will take several years to read out safety and efficacy.
• Expansion to other organs will require new delivery systems and vector designs.
• Any "longevity" use would require massive, long-term safety data and likely decades of follow-up.

For now, this is a scientific milestone, not a consumer option.

7. References

8. FAQ